



152 1654  
18

WST108AUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Appln. No. : 10/532,971 Confirmation No.: 4656  
Applicant : Caton  
Filed : April 27, 2005  
TC/A.U. : 1654  
Examiner : unassigned  
Customer No. : 00270  
Title : MOUSE MODEL FOR AUTOIMMUNE DISORDERS

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Applicant submits to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08A/B is attached and copies of the documents are enclosed herewith. This Information Disclosure Statement is submitted more than three months from the filing date of this, but before the receipt of a first Office Action. Therefore, no fees are believed due.

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to or deposited with the United States Postal Service with sufficient postage in an envelope addressed to Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or Printed Name	Summer Uchin	Date	Aug. 24, 2006

6

## **REMARKS**

Listed below are documents cited in the International Search Report dated November 22, 2004 in the corresponding International Patent Application No. PCT/US03/31519, filed October 27, 2003. A copy of the Report is enclosed, together with copies of the documents.

- (i) RILEY et al., "Graded Deletion and Virus-Induced Activation of Autoreactive CD4+ T Cells", *J. Immunol.*, 265:4870-4876 (November 1, 2000)
- (ii) BOT et al., "Cellular Mechanisms Involved in Protection Against Influenza Virus Infection in Transgenic Mice Expressing a TCR Receptor Specific For Class II Hemagglutinin Peptide in CD4+ and CD8+ Cells", *J. Immunol.* 160:4500-4507 (May 1, 1998)
- (iii) SHIH et al., "A Major T Cell Determinant from the Influenza Virus Hemagglutinin (HA) can be a Cryptic Self Peptide in HA Transgenic Mice" *Int. Immunol.*, 9(2):249-261 (February, 1997)
- (iv) RILEY et al., "CD4+ Cells that Evade Deletion by a Self Peptide Display Th1-Biased Differentiation", *Eur. J. Immunol.*, 31:311-319 (January, 2001)

The month of publication for documents AAR, AAV, and AAZ could not be determined. The years of publication for these documents are sufficiently earlier than the effective US filing date and/or the foreign priority date of the present application so that the particular month of publication of the documents is not in issue (MPEP 609).

The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached Form PTO/SB/08A/B during the course of examination of this application.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or during the pendency of this application, or credit any overpayment in any fees to our Deposit Account Number 08-3040.

Respectfully submitted,

HOWSON & HOWSON  
Attorneys for Applicants

By Mary E. Bak  
Mary E. Bak  
Registration No. 31,215  
Suite 210  
501 Office Center Drive  
Fort Washington, PA 19034  
Telephone: (215) 540-9200  
Telefacsimile: (215) 540-5818



# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/532,971
		Filing Date	April 27, 2005
		First Named Inventor	Caton
		Art Unit	1654
		Examiner Name	unassigned
Total Number of Pages in This Submission	6	Attorney Docket Number	WST108AUSA

ENCLOSURES (Check all that apply)			
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input checked="" type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):  <input checked="" type="checkbox"/> International Search Report	
<div style="border: 1px solid black; padding: 2px;">Remarks</div> <p>Customer No. 00270</p>			

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Howson and Howson		
Signature			
Printed name	Mary E. Bak		
Date	Aug. 24, 2006	Reg. No.	31,215

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature	
Typed or printed name	Summer Uchin
Date	Aug. 24, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Approved for use through 06/30/2006.  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/532,971
(Use as many sheets as necessary)				Filing Date	April 27, 2005
				First Named Inventor	Caton
				Art Unit	1654
				Examiner Name	unassigned
Sheet	1	of	2	Attorney Docket Number	WST108AUSA

#### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AR	RILEY et al., "Graded Deletion and Virus-Induced Activation of Autoreactive CD4+ T Cells", J. Immunol., 265:4870-4876 (November 1, 2000)	
	AS	BOT et al., "Cellular Mechanisms Involved in Protection Against Influenza Virus Infection in Transgenic Mice Expressing a TCR Receptor Specific For Class II Hemagglutinin Peptide in CD4+ and CD8+ Cells", J. Immunol. 160:4500-4507 (May 1, 1998)	
	AT	SHIH et al., "A Major T Cell Determinant from the Influenza Virus Hemagglutinin (HA) can be a Cryptic Self Peptide in HA Transgenic Mice" Int. Immunol., 9(2):249-261 (February, 1997)	
	AU	RILEY et al., "CD4+ Cells that Evade Deletion by a Self Peptide Display Th1-Biased Differentiation", Eur. J. Immunol., 31:311-319 (January, 2001)	
	AV	HEATH et al., "Expression of Two T Cell Receptor $\alpha$ -Chains on the Surface of Normal Murine T Cells" Eur. J. Immunol., 25:1617-1623 (June, 1995)	
	AW	HOLMDAHL et al., "Type II Collagen Autoimmunity in Animals and Provocations Leading to Arthritis" Immunol. Rev., 118:193-232 (December, 1990)	
	AX	JORDAN et al., "Anergy and Suppression Regulate CD4+ T Cell Responses to a Self Peptide" Eur. J. Immunol., 30:136-144 (January, 2000)	
	AY	KEFFER et al., "Transgenic Mice Expressing Human Tumour Necrosis Factor: A Predictive Genetic Model of Arthritis" EMBO J., 10(13):4025-4031 (December, 1991)	
	AZ	KOUSKOFF et al., "A Vector Driving the Expression of Foreign cDNAs in the MHC Class II-Positive Cells of Positive Mice" J. Immunol. Methods 166:287-291 (December 3, 1993)	
	AAR	LIPSKY, "Rheumatoid Arthritis" in Harrison's Principles of Internal Medicine, Fauci et al., Eds., McGraw-Hill Publishers New York, NY: pp. 1880-1888 (1998)	
	AAS	MARRACK et al., "Autoimmune Disease: Why and Where it Occurs" Nat. Med., 7(8): 899-905 (August, 2001)	
	AAT	MATSUMOTO et al., "Arthritis Provoked by Linked T and B Cell Recognition of a Glycolytic Enzyme" Science, 286: 1732-1735 (November 26, 1999)	
	AAU	MCCUSKER et al., "HLA-D Region Antigens in Patients with Rheumatoid Arthritis" Arth. Rheumatism, 34(2): 192-197 (February, 1991)	
	AAV	NEPOM, "Major Histocompatibility Complex-Directed Susceptibility to Rheumatoid Arthritis" Adv. Immunol., 68:315-332 (1998)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.



U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 06/30/2006.

Approved for use through 06/30/2006.  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(Use as many sheets as necessary)</i></p>		<b>Complete if Known</b>	
		Application Number	10/532,971
		Filing Date	April 27, 2005
		First Named Inventor	Caton
		Art Unit	1654
		Examiner Name	unassigned
Sheet	2	of	2
Attorney Docket Number			WST108AUSA

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to be considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). \* Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.

*If you need assistance in completing the form, call 1-800-PTO-919 and select option 3.*